Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087934 | 0.93 | NAAA (0.40) | NAAAHIF1ATSHR | |
| SCHEMBL348397 | 0.84 | NAAA (0.34) | NAAAHIF1A | |
| SCHEMBL24259322 | 0.78 | ALDH1A1 (0.34) | HIF1ATSHR | |
| SCHEMBL29263731 | 0.76 | HRH1 (0.58) | NAAA | |
| SCHEMBL29263644 | 0.75 | HRH1 (0.61) | NAAA | |
| SCHEMBL7036030 | 0.75 | NAAA (0.47) | NAAA | |
| SCHEMBL7465934 | 0.74 | HIF1A (0.33) | HIF1ATSHR | |
| SCHEMBL1258644 | 0.72 | NAAA (0.44) | NAAA | |
| SCHEMBL29104167 | 0.72 | NAAA (0.48) | NAAATSHR | |
| SCHEMBL6168562 | 0.71 | HDAC2 (0.46) | NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287338-A1 | Metalloproteinase inhibitor compounds | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| US-7122551-B2 | Metalloproteinase inhibitor compounds | ASTRAZENECA AB (SE) | 2006-10-17 | — | — | US | disclosed |
| CN-1247547-C | Piperidine and piperazine substituted N-hydroxyformamides as inhibitors of metalloproteinases | ASTRAZENECA AB (SE) | 2006-03-29 | — | — | CN | disclosed |
| US-20040176386-A1 | Compounds | ASTRAZENECA AB (SE) | 2004-09-09 | — | — | US | disclosed |
| US-6734183-B2 | USEFUL AS METALLOPROTEINASE INHIBITOR; PIPERAZINO-SULFONAMIDE OR PIPERIDINO-SULFONAMIDE COMPOUND | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| CN-1418197-A | Piperidine and piperazine substituted N-hydroxycarboxamides as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2003-05-14 | — | — | CN | disclosed |
| EP-1261590-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| US-20020022628-A1 | Compounds | ASTRAZENECA AB (SE) | 2002-02-21 | — | — | US | disclosed |
| WO-2001062742-A1 | PIPERIDINE- AND PIPERAZINE SUBSTITUTED N-HYDROXYFORMAMIDES AS INHIBITORS OF METALLOPROTEINASES | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022628-A1 | Compounds | MMP13, MMP11, MMP3 | NAAA 1907/4885HIF1A 906/4885TSHR 4597/4885 |
| US-20060287338-A1 | Metalloproteinase inhibitor compounds | TIMP3, MMP2, MMP13 | NAAA 1165/4885HIF1A 1188/4885TSHR 4551/4885 |
| US-20040176386-A1 | Compounds | MMP13, MMP11, MMP3 | NAAA 1907/4885HIF1A 906/4885TSHR 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.